Adaptimmune Therapeutics plc

Designing and delivering cell therapies to transform the lives of people with cancer.

Data update from our Phase 1 SURPASS clinical trial with our next-gen therapy ADP-A2M4CD8

Latest Corporate Deck Press Release Video

<
>

Designing and delivering cell therapies to transform the lives of people with cancer.  

An update on our Allogeneic Platform and a new collaboration to research, develop, and commercialize cancer-targeted allogeneic t-cell therapies

Press Release Video Replay Presentation

<
>

Designing and delivering cell therapies to transform the lives of people with cancer.  

SPEARHEAD-1 initial data is out

Latest Corporate Deck Press Release

<
>

Designing and delivering cell therapies to transform the lives of people with cancer.  

Adaptimmune Reports Second Quarter Financial Results and Business Update

Webcast Press Release

<
>

Designing and delivering cell therapies to transform the lives of people with cancer.  

Certified Best Place to Work-US and Great Place to Work-UK. Visit our Careers page to join our growing team

Careers
<
>
Designing and delivering cell therapies to transform the lives of people with cancer.  

Adaptimmune’s mission is to transform the lives of people with cancer by designing and delivering cell therapies

Learn More
<
>
Our Clinical Trials

Advancing T-cell therapy through world-class expertise

Our main priority at Adaptimmune is to improve the outcomes of patients who are suffering from cancer via immunotherapy.

View Our Clinical Trials
For Patients and Families

Helpful resources for patients and their families

Our efforts in immunotherapy are aimed at improving outcomes for patients who are living with cancer. Our resources are available to both patients their families.

View Our Resources
Our Pipeline

SPEAR-heading the Cancer Revolution

An industry leading TCR pipeline that targets solid tumors

We build affinity-enhanced T-cell therapies aimed at destroying cancer cells. Our therapies work with the immune system to improve the detection and targeting of those cancer cells.

View Our Pipeline

Our Robust Manufacturing Process

Delivering affinity-enhanced TCRs to patients

Our manufacturing process provides world class capabilities for designing and delivering cell which enables us to efficiently supply patients in our clinical trials.

Learn More

Latest News

Adaptimmune to Report Q3 2021 Financial Results and Business Update on Thursday, November 4, 2021

Read Press Release View All News

Adaptimmune to Present Data Updates at Upcoming CTOS and SITC Meetings

Read Press Release

Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial

Read Press Release

Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies

Read Press Release